# PK14105

| | | | |
|---|---|---|---|
| **Cat. No.:** | HY-100346 | | |
| **CAS No.:** | 107257-28-3 | | |
| **Molecular Formula:** | $C_{21}H_{20}FN_3O_3$ | | |
| **Molecular Weight:** | 381.4 | | |
| **Target:** | Others | | |
| **Pathway:** | Others | | |
| **Storage:** | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 2 years |
| | | -20°C | 1 year |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : ≥ 30 mg/mL (78.66 mM)

* "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Mass / Solvent / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.6219 mL | 13.1096 mL | 26.2192 mL |
| | 5 mM | 0.5244 mL | 2.6219 mL | 5.2438 mL |
| | 10 mM | 0.2622 mL | 1.3110 mL | 2.6219 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

PK14105 is a biological evaluation as a potential radioligand for PET studies of PBBS receptors.in vivo binding experiments, in which PK 14105 was injected into rats with unilaterally lesioned striata, demonstrate that PK 14105 rapidly crosses the blood-brain-barrier and that there is a marked retention of radioactivity in the lesioned striatum not seen in the unlesioned striatum or cerebellar vermis[1]. It can also inhibit receptor ligands, calcium channel ligands and co-transporter in all salivary glands[2].

## REFERENCES

[1]. Pascali C et al. The radiosynthesis of [18F]PK 14105 as an alternative radioligand for peripheral type benzodiazepine binding sites. Int J Rad Appl Instrum A. 1990;41(5):477-82.

[2]. Franklin C. Wong et al. Affinity Labeling of Membrane Receptors Using Tissue-Penetrating Radiations. Biomed Res Int. 2013, 503095.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA